{
  "retracted": false,
  "timestamp": 1585699200000,
  "updates": [
    {
      "timestamp": 1592350875737,
      "identifier": {
        "doi": "10.1136/jitc-2019-000347corr1"
      },
      "type": "correction"
    }
  ],
  "identifier": {
    "doi": "10.1136/jitc-2019-000347"
  },
  "journal": "Journal for ImmunoTherapy of Cancer",
  "publisher": "BMJ",
  "title": "Correction:Phase 2 study of pembrolizumab in patients with advanced rare cancers"
}
